NOV 09, 2017 01:30 PM PST

Importance of Measuring the Inhibition of Platelet Thromboxanes by Aspirin in Cardiovascular Disease Management and Prevention

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Medical Director, Corgenix Inc.
    Biography
      Luis R. Lopez, M.D., is the founder of Corgenix, Inc. (Broomfield, Colorado, USA) and currently serves as the Company's Medical Director. He received his MD degree in Lima, Peru, with Internal Medicine residency and postgraduate training in Clinical Immunology and Rheumatology at the University of Colorado Health Sciences Center in Denver Colorado. Dr. Lopez has worked in the field of immunodiagnostic of systemic autoimmune diseases including autoimmune-mediated atherothrombotic syndromes such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Recent work and publications have included serologic biomarkers to assess the risk of atherosclerotic cardiovascular diseases (CVD) such as oxidized low-density lipoprotein, ß2-Glycoprotein I and CRP complexes as well as pro-thrombotic platelet (urinary thromboxanes, 11dhTxB2) and inflammatory-derived F2-Isoprostanes metabolites.

    Abstract:

    Antiplatelet therapy with aspirin (ASA) is widely used in cardiovascular disease (CVD) prevention because it inhibits platelet cyclooxygenase-1 (COX-1) and thromboxane A2 (TXA2)-mediated platelet aggregation, but not everyone fully benefit from ASA due to incomplete TXA2 suppression. Among the mechanisms to explain ASA failure (poor ASA response or ASA resistance), oxidative stress and inflammation have emerged as relevant factors. The relationship of urinary 11-dehydro-thromboxane B2 (11dhTxB2), an inactive stable metabolite of TxA2, and oxidative stress (urinary 8-isoPGF2α) in a cohort of stable coronary artery disease (CAD) patients on ASA treatment with the risk of adverse outcomes (mortality) was investigated. In this session, the effect of aspirin on platelet cyclooxygenase COX-1 and thromboxane (TxA2) inhibition, and its use in cardiovascular disease prevention will be reviewed. This review will include current laboratory measurement of urinary 11dhTxB2, a stable inactive metabolite of TxA2, to assess ASA response as a risk factor of CVD including mortality. Study results confirmed that laboratory measurement of urinary 11dhTxB2 represents a strong independent risk factor for all-cause mortality among stable CAD patients on ASA therapy. These results also indicate that 8-isoPGF2α and COX-2 thromboxane production not affected by ASA may maintain platelet hyperactivity irrespective of COX-1 inhibition. Poor ASA inhibition of 11dhTxB2 (ASA resistance) may prompt additional anti-oxidative and/or anti-inflammatory therapy in these patients aimed at modifying 5-year mortality risk.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    JUL 30, 2019 10:00 AM PDT
    C.E. CREDITS
    JUL 30, 2019 10:00 AM PDT
    DATE: July 30, 2019TIME: 10:00am PT/ 1:00pm ET The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high...
    MAR 26, 2019 02:00 PM PDT
    C.E. CREDITS
    MAR 26, 2019 02:00 PM PDT
    DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
    Loading Comments...
    Show Resources